It blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle. Its action is, therefore, independent of the pathways for angiotensin II synthesis. OSART has more than a 12,500-fold greater affinity for the AT1 receptor than for the AT2 receptor. It is indicated for the treatment of hypertension, to lower blood pressure.
